Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Pautier P, Guillemet C, Sabatier R, Classe J-M, Petit T, Leblanc E, Marchal F, Colombo P-E, Barranger E, Savoye A-M, Bosquet L, Ray-Coquard I, Carton M, Colomban O, Rodrigues M Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas. Int J Gynecol Cancer. 2025-01-06. doi:10.1136/ijgc-2024-005815
Tabet I, Candiello E, Fenou L, Velazquez C, Jacot W, Ribeyre C, Sardet C, Theillet C Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe.. Cancer Research. 2025;in press.
Di Michele M, Attina A, Roux P-F, Laguesse S, Florido J, Houdeville M, Choquet A, Encislai B, Arena G, De Blasio C, Wendling O, Frenois F-X, Papon L, Stuani L, Fuentes M, Jahannault Talignani C, Rousseau M, Guégan J, Buscail Y, Dupré P, Michaud H-A, Rodier G, Bellvert F, Kulyk H, Ferraro Peyret C, Mathieu H, Close P, Rapino F, Chaveroux C, Pirot N, Rubio L, Torro A, Sorg T, Ango F, Hirtz C, Compan V, Lebigot E, Legati A, Ghezzi D, Nguyen L, David A, Sardet C, Lacroix M, Le Cam L E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development. Nat Commun. 2025;16(1):67. doi:10.1038/s41467-024-55444-y
Bardia A, Hu X, Dent R, Yonemori K, Barrios C, O'Shaughnessy J, Wildiers H, Pierga J-Y, Zhang Q, Saura C, Biganzoli L, Sohn J, Im S-A, Jacot W, Begbie N, Ke J, Patel G, Curigliano G Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391(22):2110-2122. doi:10.1056/NEJMoa2407086
Colombo P-E, Druet C, Mourregot A, Riou O, Rouanet P, Taoum C Robotic posterior pelvic exenteration for locally advanced rectal cancer-A video vignette. Colorectal Dis. 2024;26(10):1845-1848. doi:10.1111/codi.17147
Boissière-Michot F, Chateau M-C, Lafont V, Crapez E, Sharma P, Roger P, Guiu S, Jacot W Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features. Front Immunol. 2024;15. doi:10.3389/fimmu.2024.1507371
Colombo P-E, Taoum C, Fabbro M, Quesada S, Rouanet P, Ray-Coquard I Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2024;202. doi:10.1016/j.critrevonc.2024.104469
Massa D, Vernieri C, Nicolè L, Criscitiello C, Boissière-Michot F, Guiu S, Griguolo G, Miglietta F, Vingiani A, Lobefaro R, Taurelli Salimbeni B, Pinato C, Schiavi F, Brich S, Pescia C, Fusco N, Pruneri G, Fassan M, Curigliano G, Guarneri V, Jacot W, Dieci M Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer. J Natl Cancer Inst. 2024;116(12):1914-1927. doi:10.1093/jnci/djae178
Puszkiel A, Dalenc F, Tafzi N, Marquet P, Debled M, Jacot W, Venat-Bouvet L, Ferrer C, Levasseur N, Paulon R, Dauba J, Evrard A, Mauriès V, Filleron T, Chatelut E, Thomas F, White-Koning M Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients. Eur J Pharm Sci. 2024;199. doi:10.1016/j.ejps.2024.106809
Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel J-S, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delaloge S, Bellera C First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Eur J Cancer. 2024;196. doi:10.1016/j.ejca.2023.113422
Bardol T, Eslami-S Z, Masmoudi D, Alexandre M, Duboys de Labarre M, D'Hondt V, Guiu S, Kurma K, Cayrefourcq L, Jacot W, Alix-Panabières C First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study. Cancer Med. 2024;13(1):e6843. doi:10.1002/cam4.6843
Houvenaeghel G, Classe J-M, Chauvet M-P, Colombo P-E, Jouve E, Reyal F, Daraï E, Rouzier R, Faure-Virelizier C, Gimbergues P, Coutant C, Mazouni C, Azuar A-S, Martino M, Bouteille C, Cohen M, de Nonneville A Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. Cancers (Basel). 2024;16(19):3317. doi:10.3390/cancers16193317
Faravel K, Jarlier M, Meignant L, Thomaso M, Del Rio M, Jacot W, Stoebner A Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2). BMJ Open. 2024;14(1):e075378. doi:10.1136/bmjopen-2023-075378
Eslami-S Z, Cortés-Hernández L, Sinoquet L, Gauthier L, Vautrot V, Cayrefourcq L, Avoscan L, Jacot W, Viala M, Thomas Q, Lamy P-J, Quantin X, Gobbo J, Alix-Panabières C Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. Br J Cancer. 2024;130(1):63-72. doi:10.1038/s41416-023-02491-9
Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, Jacot W, Sardet C, Theillet C CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer. Cancer Lett. 2024;589. doi:10.1016/j.canlet.2024.216820
Bruciamacchie M, Garambois V, Vie N, Bessede T, Michaud H-A, Gros L, Bonnefoy N, Robin M, Brager D, Bigot K, Evrard A, Pourquier P, Colinge J, Mathonnet M, Belhabib I, Jean C, Bousquet C, Colombo P-E, Jarlier M, Gongora C, Larbouret C ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Br J Cancer. 2024-11-29. doi:10.1038/s41416-024-02904-3
Antoine A, Pérol D, Robain M, Bachelot T, Choquet R, Jacot W, Ben Hadj Yahia B, Grinda T, Delaloge S, Lasset C, Drouet Y Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation. Eur J Cancer. 2024;213. doi:10.1016/j.ejca.2024.115072
Alexandre M, Jacot W [Therapeutic advances in HER2+ breast cancer]. Rev Prat. 2023;73(4):355-359.
Hurvitz S, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu J, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning J-W, Curigliano G, Perez-Garcia J, Kim S-B, Petry V, Huang C-S, Li W, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5
Quesada S, Jacot W The quest for the optimal biomarker: is extending the spectrum of targeted PIK3CA mutations in breast cancer carcinoma worthwhile?. Ann Transl Med. 2023;11(11):393. doi:10.21037/atm-23-1608
Mailliez A, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero J-M, Petit T, Mouret-Reynier M, Eymard J-C, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Simon G, Jacot W, Delaloge S Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2023;152(5):921-931. doi:10.1002/ijc.34304
Alcaraz L, Mallavialle A, Mollevi C, Boissière-Michot F, Mansouri H, Simony-Lafontaine J, Laurent-Matha V, Chardès T, Jacot W, Turtoi A, Roger P, Guiu S, Liaudet-Coopman E SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. Int J Cancer. 2023;152(6):1243-1258. doi:10.1002/ijc.34345
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeulin T, Emile G, Ung M, Robert M, Desmoulins I, Jouannaud C, Uwer L, Marc Ferrero J, Mouret-Reynier M-A, Jacot W, Chevrot M, Delaloge S Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program. Oncologist. 2023;28(10):e867-e876. doi:10.1093/oncolo/oyad137
Grinda T, Antoine A, Jacot W, Cottu P-H, Frenel J-S, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret Reynier M-A, Levy C, Ferrero J-M, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Pérol D, Pistilli B, Delaloge S Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. Eur J Cancer. 2023;189. doi:10.1016/j.ejca.2023.05.023
Griguolo G, Aldegheri V, Bottosso M, Pittaro A, Caumo F, Guarascio M, Busato F, Miglietta F, Jacot W, Dieci M, Guarneri V Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients. Int J Cancer. 2023;153(6):1217-1226. doi:10.1002/ijc.34571
Institut de Recherche en Cancérologie de
